CN1679717A - External-applied medicine for treating terminal neuritis and preparation thereof - Google Patents
External-applied medicine for treating terminal neuritis and preparation thereof Download PDFInfo
- Publication number
- CN1679717A CN1679717A CN 200510009240 CN200510009240A CN1679717A CN 1679717 A CN1679717 A CN 1679717A CN 200510009240 CN200510009240 CN 200510009240 CN 200510009240 A CN200510009240 A CN 200510009240A CN 1679717 A CN1679717 A CN 1679717A
- Authority
- CN
- China
- Prior art keywords
- parts
- rhizoma
- medicine
- aconiti kusnezoffii
- radix notoginseng
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
An exterior-applied Chinese medicine in the form of gel for treating peripheral neurtitis is prepared from aconite root, Chuan-xiong rhizome and notoginseng. Its advantages are high curative effect, and no pollution to clothes.
Description
Technical field:
The present invention relates to a kind of medicine for external use for the treatment of peripheral neuritis and preparation method thereof, mongolian medicine field in belonging to.
Background technology:
Diabetes, rheumatism, muscular dystrophy etc. are the main diseases of concurrent peripheral neuritis, and especially diabetes cause that the peripheral neuritis disease is in the great majority.Diabetes peripheral nerve pathological changes is one of diabetes three big complication, also is one of difficult problem in the diabetes study field, and along with China's constant development of economy and associated life style change, the prevalence of diabetes increases just with surprising rapidity.China's onset diabetes rate is 3.2% at present according to statistics, estimate that the whole nation has 3,000 ten thousand patients approximately, wherein the diabetic peripheral neuritis age is 50%～85% greater than 40 years old person's sickness rate, the course of disease is 72% greater than 20 years person's sickness rate, brings heavy burden for family and society for so high ill crowd.Therefore, a kind of medicine for the treatment of diabetic peripheral neuritis of research and development is highly significant.
A lot of to the research of this disease both at home and abroad at present, but still do not have a kind of good Therapeutic Method, domestic most application neurotrophy medicine, as vitamin B complex and vasodilation treatment, and adopt inositol abroad in recent years, aldose reductase inhibitor etc., though certain curative effect is arranged, side effect is also many.Middle Mongolian medicine's medicine is brought into play the advantage of oneself in this respect, and big cholic trial has also been done in in-depth to some extent on route of administration and dosage form in determination of treatment based on pathogenesis obtained through differentiation of symptoms and signs,
Summary of the invention:
The object of the present invention is to provide a kind of medicine for external use for the treatment of peripheral neuritis.This medication is imitated remarkable, safe and reliable, can remove the clinical symptoms of peripheral neuritis, can improve limb microcirculation disturbance and europathology state, by neuroregulation improved effect such as numb limbs and tense tendons, pain, symptoms such as sensory disturbance.
Purpose of the present invention also provides a kind of preparation method for the treatment of the medicine for external use of peripheral neuritis.
Purpose of the present invention is implemented by following technical scheme:
Peripheral lesions such as skin numbness, pain and paraesthesia due to the diabetic peripheral neuritis that the Mongolian medicine makes a definite diagnosis modern medicine are taken the turbid urine disease skin injury that protracted course of disease caused all the year round as, and the teleneuron damage that other disease is caused belongs to outer aortic arch syndrome category.At 18th century Mongolian medicine's classics " a collection of selected materials of Mongolian medicine's medicine " medium cloud: " turbid urine is unclear, often has fly to troop on the urine mark, has a liking for food and excessive phlegm saliva ".The Four-Volume Medical Code claims: multiple changes such as " skin carbuncle skin ulcer more can not appear in turbid urine disease ' conspicuous complying with ' Sheng person's symptom concealment partially all the year round if will not treat ".Think within this disease because of being that " Ba Dagan " contains partially, and with " conspicuous according to " modification together, make the dysequilibrium of three seven elements; Exopathogenic factor is an improper diet, and daily life is not normal,, salt greasy as surfeit, sweet food and the cold and cool and food that heavily stagnates, the ground of the humidity that hangs up one's hat, or disorder of emotion, forced labour mistake degree etc. all can cause liver, kidney is scorching and deterioration, and then elite and waste matter decompose not normally, and the result drains unusually, causes the turbid urine disease." Ba Dagan ", " conspicuous complying with " mixed type body constitution person, chronic not disappearing property patient easily suffers from this disease.Can be divided into acute and chronic two kinds clinically.Mainly show as frequent micturition, hyperhidrosis, stench, halitosis, last Hubei Province is dry, turbid urine; Weight person's heating, palpitation and insomnia, limbs pain.This disease protracted course of disease causes skin injury, be because the key of its morbidity pathogenesis is that smart poor decomposition is not normal, thereby " Xieri Wusu Symptom " increases, and to external diffusion, involves outer the lung-pulse, finally causes skin injury and paresthesia of skin.Mongolian medicine's method of treatment is should be to adjust three, and the cold relieving kidney tonifying is a principle, notices that simultaneously the void of blood " uncommon day " is contained; To chronic or existing visual disorder, skin carbuncle skin ulcer person, take defence " conspicuous complying with " to contain partially, dry " Xieri Wusu Symptom ", and logical the lung-pulse kills " gluing " in the time of row " conspicuous complying with " blood, and pain relieving is to suit the medicine to the illness.
The nerve injury that other diseases causes i.e. the main clinical manifestation of outer aortic arch syndrome, states in " Mongolian medicine's encyclopedia ": " suffer from acroanesthesia, pain, swelling appears in severe patient, even contracture ".Method of treatment basically identical to its Therapeutic Method and the sick chronic skin injury of turbid urine.Because outer the lung-pulse is also involved in the final development of chronic turbid urine disease, causes same pathological process.
Regulate the function of " conspicuous according to, Ba Dagan ", blood circulation promoting and blood stasis dispelling, pain relieving.Be used for the diseases such as nervous lesion that skin numbness, pain, paraesthesia and other diseases due to the peripheral neuritis cause.
Said in the literary composition " Ba Dagan " is expectorant, wet, cold, body fluid; " conspicuous complying with " is gas, wind, the lung-pulse; " uncommon day " is pry-, gallbladder.Being commonly referred to as three of Mongolian medicine, is life three elements.Said in the literary composition " gluing ": be the exopathogen paathogenic factor.
Medicament selection Radix Aconiti Kusnezoffii of the present invention, Rhizoma Chuanxiong and Radix Notoginseng make up, and make each medicine produce synergism these drug regimens, thereby can effectively treat peripheral neuritis.Wherein select for use Radix Aconiti Kusnezoffii to be because Radix Aconiti Kusnezoffii is warm in nature, acrid in the mouth; Imitate light, very toxic.Can kill " gluing ", pain relieving, dry " Xieri Wusu Symptom ".Say in " recognizing the white brilliant medicine mirror of medicine ": " all skin infection carbuncle and skin ' glue ' disease, but Radix Aconiti Kusnezoffii ".《 Tie Rosary " say: " Radix Aconiti Kusnezoffii is very toxic, and effect is strong, so it is extremely strong to end the twinge function, eliminates the poison of disease and suffers from " is all changes after damaging at " Xieri Wusu Symptom " that increase and outer the lung-pulse, promptly effects a permanent cure and the doctor shows.Radix Aconiti Kusnezoffii and Rhizoma Chuanxiong match and purify the blood, and short blood fortune to improve QI-blood circulation (being activating blood circulation to dissipate blood stasis), matches with Radix Notoginseng, and is because of Radix Notoginseng sweet in the mouth, hardship, cool in nature.Because of Radix Notoginseng energy astringing to arrest bleeding, the detumescence of curing the wound, pain relieving mainly is the inclined to one side Sheng of blood " uncommon day " in prevention course of disease later stage.Simultaneously with the Radix Aconiti Kusnezoffii reducing swelling and alleviating pain that accompanies, promote it " conspicuous according to " blood operation of the lung-pulse.During Fang Zhongsan flavor was formed, the first two the flavor soaking of flavor property of medicine or Wen Erxin were the nature and flavor first choice of " Ba Dagan, conspicuous according to " of dispelling; Only the Radix Notoginseng nature and flavor are bitter and cool, are that contain partially prevention blood, " uncommon day ".Radix Aconiti Kusnezoffii kills " glue " in the prescription of the present invention, and dry " Xieri Wusu Symptom ", with the Radix Notoginseng pain relieving of accompanying, detumescence effects a permanent cure and the doctor shows, and effects a permanent cure with the Rhizoma Chuanxiong activating blood circulation to dissipate blood stasis that matches.So this Chinese medicine is effectively to treat the peripheral nerve dysfunction that diabetes etc. cause.
In order to reach better curative effect, medicine of the present invention also makes up with Rhizoma Kaempferiae, and this is hot because selecting Rhizoma Kaempferiae nature and flavor heat for use, imitates sharp.Can dispel " Ba Dagan, conspicuous complying with " rare blood (being equivalent to the traditional Chinese medical science invigorates blood circulation), regulating stomach temperature." theoretical continuous " claims it: " dispel ' Ba Dagan, conspicuous complying with ' can change congestion "." mongolian medicine " explains it: " to stomach temperature decline and smart poor separation barrier person, be that monarch's four flavor white agents are executed and controlled with the Rhizoma Kaempferiae." " golden light note collection " also claim: " and the Rhizoma Kaempferiae acrid in the mouth, hot in nature; Imitate sharp, light ... ", be cold relieving, rare blood, property, flavor, the effect of the smart poor separation of promotion; be that sensing disease root and endogenous cause of ill are promptly effected a permanent cure, matching with Rhizoma Chuanxiong purifies the blood, and short blood is transported, and is to improve QI-blood circulation (being activating blood circulation to dissipate blood stasis); match with Radix Notoginseng, because of Radix Notoginseng sweet in the mouth, hardship, cool in nature.The energy astringing to arrest bleeding, the detumescence of curing the wound, pain relieving.The blood " uncommon day " that mainly is the prevention course of disease later stage is contained partially, simultaneously with the Radix Aconiti Kusnezoffii reducing swelling and alleviating pain that accompanies, promotes it " conspicuous according to " blood operation of the lung-pulse, is adjuvant.During Fang Zhongsi flavor is formed, first three medicine of distinguish the flavor of: Radix Aconiti Kusnezoffii, Rhizoma Chuanxiong, Rhizoma Kaempferiae, nature and flavor soaking or Wen Erxin are the nature and flavor first choice of " Ba Dagan, conspicuous complying with " of dispelling; Only the Radix Notoginseng nature and flavor are bitter and cool, are that contain partially prevention blood, " uncommon day ".Radix Aconiti Kusnezoffii kills " glue " in the prescription of the present invention, and dry " Xieri Wusu Symptom ", with the Radix Notoginseng pain relieving of accompanying, detumescence effects a permanent cure and doctor's table, and Rhizoma Kaempferiae is dispelled " Ba Dagan, conspicuous complying with ", effects a permanent cure with the Rhizoma Chuanxiong activating blood circulation to dissipate blood stasis that matches.So this Chinese medicine is effectively to treat the peripheral nerve dysfunction that diabetes etc. cause.
In order to obtain optimum curative effect, medicine of the present invention also can add Rhizoma Corydalis and Rhizoma Curcumae Longae on the basis of said medicine, and this is because of Rhizoma Corydalis acrid in the mouth bitterness temperature, and hot diffusing temperature is logical, and " stagnation of QI in the energy promoting the circulation of blood, so stasis in the gas is all pains about specially controlling all over the body." Rhizoma Curcumae Longae acrid in the mouth bitterness temperature, Xin Wen and hold concurrently bitter, can outer dispersing wind and cold damp, interior qi and blood circulation promotion, inducing menstruation to relieve menalgia is used for rheumatic arthralgia.This two flavors medicine can both inducing menstruation to relieve menalgia, matches with above-mentioned all medicines, more can effectively treat the peripheral nerve dysfunction that diabetes etc. cause.
The consumption of drug component of the present invention is also groped to sum up to draw through the inventor in a large number.The each component consumption is for all to have better curative effect in the following weight parts scope:
120～360 parts of Radix Aconiti Kusnezoffii, 25～100 parts of 240～480 parts of Rhizoma Chuanxiongs and Radix Notoginseng.
Be preferably: 200～300 parts of described raw material Radix Aconiti Kusnezoffii, 300～450 parts of Rhizoma Chuanxiongs, 50～80 parts of Radix Notoginseng.
Most preferably be: 260 parts of Radix Aconiti Kusnezoffii, 430 parts of Rhizoma Chuanxiongs, 50 parts of Radix Notoginseng.
Drug dose of the present invention can also be: 120～360 parts of Radix Aconiti Kusnezoffii, 480 parts of 240～480 parts of Rhizoma Chuanxiongs, 25～100 parts of Radix Notoginseng and Rhizoma Kaempferiae 200～｀.
Be preferably: 200～300 parts of described raw material Radix Aconiti Kusnezoffii, 300～450 parts of Rhizoma Chuanxiongs, 50～80 parts of Radix Notoginseng, 240～400 parts of Rhizoma Kaempferiaes.
Most preferably be: 260 parts of described raw material Radix Aconiti Kusnezoffii, 420 parts of Rhizoma Chuanxiongs, 70 parts of Radix Notoginseng, 260 parts of Rhizoma Kaempferiaes.
Drug dose of the present invention can also be: 120～360 parts of Radix Aconiti Kusnezoffii, 240～480 parts of Rhizoma Chuanxiongs, 25～100 parts of Radix Notoginseng, 200～480 parts of Rhizoma Kaempferiaes, 80～160 parts in 50～160 parts of Rhizoma Corydalis and Rhizoma Curcumae Longae.
Be preferably: 200～300 parts of Radix Aconiti Kusnezoffii, 300～450 parts of CHUANSHAO, 50～80 parts of Radix Notoginseng, 240～400 parts of Rhizoma Kaempferiaes, 80～130 parts of Rhizoma Corydalis, 80～120 parts in Rhizoma Curcumae Longae.
Most preferably be: 250 parts of Radix Aconiti Kusnezoffii, 420 parts of Rhizoma Chuanxiongs, 60 parts of Radix Notoginseng, 260 parts of Rhizoma Kaempferiaes, 90 parts of Rhizoma Corydalis, 100 parts in Rhizoma Curcumae Longae.
Pharmaceutical preparation of the present invention can adopt the conventional method of Chinese medicine preparation to be prepared into any external preparation.For example ointment, tincture, liniment, rubber-emplastrum etc.But better bring into play drug effect for each raw material that makes this medicine, select excellent this crude drug to be prepared into gel preparation, but these can not be used to limit protection scope of the present invention.
Preferably, medicine activity component of the present invention is made the production method of gel and is: it includes the following step:
(a): take by weighing each crude drug Radix Aconiti Kusnezoffii, Rhizoma Chuanxiong, Radix Notoginseng, standby;
(b): the Radix Aconiti Kusnezoffii of described weight proportion is ground into coarse powder with 6～10 times of amount 50%～90% ethanol percolations, collects percolate;
(c): with Rhizoma Chuanxiong, the Radix Notoginseng of described weight proportion, be ground into coarse powder, collect percolate with 6～12 times of amount 50%～95% ethanol percolations;
(d): merge (b), (c) percolate reclaims ethanol to the thick paste shape, 5～20 parts of the triethanolamine of adding weight portion proportioning, and 50～150 parts of propylene glycol, 10～60 parts of tween 80s stir;
(e): it is in 1%～3% carbomer liquid that the mixture of (d) is added to concentration, and its weight portion proportioning is 20～50 parts, fully stirs, and grinds and promptly gets the gel finished product.
If also with the Rhizoma Kaempferiae combination, its preparation method is: it includes the following step:
(a): take by weighing each crude drug Radix Aconiti Kusnezoffii, Rhizoma Chuanxiong, Radix Notoginseng, Rhizoma Kaempferiae is standby;
(b): the Radix Aconiti Kusnezoffii of described weight proportion is ground into coarse powder with 6～10 times of amount 50%～90% ethanol percolations, collects percolate;
(c): with Rhizoma Chuanxiong, the Radix Notoginseng of described weight proportion, Rhizoma Kaempferiae is ground into coarse powder with 6～12 times of amount 50%～95% ethanol percolations, collects percolate;
(d): merge (b), (c) percolate reclaims ethanol to the thick paste shape, 5～20 parts of the triethanolamine of adding weight portion proportioning, and 50～150 parts of propylene glycol, 10～60 parts of tween 80s stir;
(e): it is in 1%～3% carbomer liquid that the mixture of (d) is added to concentration, and its weight portion proportioning is 20～50 parts, fully stirs, and grinds and promptly gets the gel finished product.
If also with Rhizoma Corydalis and Rhizoma Curcumae Longae combination, its preparation method is: it includes the following step:
(a): take by weighing each crude drug Radix Aconiti Kusnezoffii, Rhizoma Chuanxiong, Radix Notoginseng, Rhizoma Kaempferiae, Rhizoma Corydalis, Rhizoma Curcumae Longae is standby;
(b): the Radix Aconiti Kusnezoffii of described weight proportion is ground into coarse powder with 6～10 times of amount 50%～90% ethanol percolations, collects percolate;
(c): with Rhizoma Chuanxiong, Radix Notoginseng, the Rhizoma Kaempferiae of described weight proportion, Rhizoma Corydalis, Rhizoma Curcumae Longae is ground into coarse powder with 6～12 times of amount 50%～95% ethanol percolations, collects percolate;
(d): merge (b), (c) percolate reclaims ethanol to the thick paste shape, 5～20 parts of the triethanolamine of adding weight portion proportioning, and 50～150 parts of propylene glycol, 10～60 parts of tween 80s stir;
(e): it is in 1%～3% carbomer liquid that the mixture of (d) is added to concentration, and its weight portion proportioning is 20～50 parts, fully stirs, and grinds promptly get loud, high-pitched sound and prick the easypro gel finished product of network.
Required various conventional adjuvant when the active constituent of medicine of the present invention can add the different exterior-applied formulation of preparation is prepared into any exterior-applied formulation commonly used with the method for Chinese medicinal of routine, as ointment, tincture, liniment, rubber-emplastrum etc.
The advantage of medicine of the present invention is: this medicine can directly act on diseased region, and is safe and reliable, evident in efficacy.Can remove the clinical symptoms of peripheral neuritis, as numb limbs and tense tendons, pain, sensory disturbances etc. also can be improved limb microcirculation disturbance and europathology state simultaneously.
This medicine has been broken through traditional exterior-applied formulations such as tincture, unguentum that Chinese medicine is prepared into.It is prepared as gel, and it is strong to have adhesiveness, with contact skin well, easily be coated with exhibition, no greasy feeling, not pollution clothes, easy cleaning, use amount is easy to control and be easy to carry, storage and advantage such as easy to use.
The specific embodiment:
Below further set forth the beneficial effect of medicine of the present invention by testing example, these experimental examples have comprised that the pharmacodynamics test of medicine of the present invention and clinical observation on the therapeutic effect test.
Experimental example 1: medicine for external use-loud, high-pitched sound of treatment peripheral neuritis is pricked the easypro gel pharmacodynamic study of network
This medicine is coated with outward and can obviously improves rat heat radiation pain threshold, and pain threshold improves 68.3%, 44.8%, 37.9% than matched group behind the high, medium and low dosage coating 20min, acts on more than the sustainable 60min.To mice hot plate analgesic activity, improve 24.6%, 29.3%, 16.7% than matched group pain threshold.Act on more than the sustainable 50min.High, medium and low dosage is respectively 19.0%, 20.3%, 7.7% to mice dimethylbenzene inflammation suppression ratio.To the rat carrageenan inflammation, high, middle dosage is remarkable inhibitory action, and low dosage is inhibition trend.Can obviously increase the open quantity of mice auricular concha blood capillary, accelerate blood circulation speed, high, medium and low dosage blood capillary opening amount increases 35.8%, 29.8%, 20.5% before than coating.The rabbit ear coating 10min bleeding from anus perfusion flow that exsomatizes is increased by 40.0%, 36.8%, 19.0% before than coating.
Purpose is measured this medicine and whether is had antiinflammatory, pain relieving, the effect of invigorating blood circulation.
1 material
The medicine loud, high-pitched sound is pricked the easypro gel of network the suitable 1g medical material of every gram, lot number 20011101 is provided by Nei Menggu Fudan Mengyao biotechnology Co.,Ltd.Diclofenac emulsion is produced by Switzerland vapour Ba-Jia Ji company, includes 1% diclofenac diethylammonium salt, lot number 264000, and authentication code (94) is defended the accurate word J-16 of medicine number.
Reagent dimethylbenzene, analytical reagent, commercially available.Carrageenin is provided by Liaoning Province medicine inspecting institute, and the time spent adds normal saline and makes 1% concentration.
Animal Wistar kind rat, Kunming mouse is provided by University of the Inner Mongol's Experimental Animal Center, the moving word 8806R011 in animal quality certification capital and 8806M35 number.Rabbit is provided by Huhehaote animal housing of pharmaceutical factory.
2 methods and result
2.1 to rat thermal radiation analgesic activity
[1]
Get rat ♂ ♀ half and half, press literature method, with 240W spotlight optically focused camera lens, 1/3 place's fixing point focuses under the rat tail, measure normal thermal radiation pain threshold (S), behind the 20min, be coated with various dose reagent product at interval at the focusing position, matched group is coated with 0.1g substrate, measures rat pain threshold (wiping ointment during mensuration) behind coating 20,40, the 60min respectively.Result of the test shows that the test drug of various dose all can improve rat thermal radiation is caused pain threshold.Compare with matched group, analgesic activity has significant difference (P＜0.01).
2.2 to mice hot plate analgesic activity
[1]
Get the ♀ mice, measure before the coating behind normal hot plate (55 ± 0.5 ℃) pain thresholds (S), be coated with the test drug of various dose on mice left and right sides metapedes and instep, measure the different time pain threshold behind the coating again and change.Measurement result shows that the various dose test drug all can improve the mice pain threshold.With matched group comparison analgesic activity significant difference (P＜0.01) is arranged.
2.3 xylol inflammatory effect
[1]
Get mice ♂ ♀ half and half, on the mouse right ear shell, be coated with 20l dimethylbenzene, treat on auris dextra, to be coated with the various dose test drug at once after dimethylbenzene is flung to, coating 20min, cut ears with shears, sweep away the auricle of ears same area, weigh with torsion balance with φ 0.8cm card punch, and difference between the calculating ears, represent the antiinflammatory action effect with the size of difference (mg).The result shows that test drug can obviously suppress the inflammation that dimethylbenzene causes.With matched group comparison antiinflammatory action significant difference (P＜0.01) is arranged.
2.4 to rat carrageenin inflammatory effect
[1]
Get rat, ♂ ♀ half and half, body weight 150-170g, measure right crus of diaphragm palm thickness (cm) with slide gauge, at the injection 0.1ml of right side foot sole of the foot portion carrageenin solution, be coated with the various dose test drug subsequently in the injection site, every 20min is coated with once, totally three times, behind injection 1h, cause scorching rat sole thickness with slide gauge mensuration every 1h.The result shows have obvious inhibition rat carrageenan inflammation, low dose group to be inflammation behind test drug height, the middle dosage coating after coating 2h and suppress trend.With matched group comparison antiinflammatory action significant difference (P＜0.01) is arranged.
2.5 to mice auricular concha capillary action
[1]
Get mice body weight 24-28g, male and female are not limit, and the ip30mg/kg pentobarbital sodium is anaesthetized, and glue with adhesive plaster and remove to test Mus auricular concha hair, observe the open quantity of auricular concha blood capillary in visual field, auricular concha fixed position with microscope low power lens (100 times), represent with the blood vessel intersection point.Coating 20min observes vessel open quantity once more.Experimental result shows that the various dose test drug all can increase the open quantity of blood capillary, and as seen, blood capillary increases slightly, blood flow is linear flow, line grain stream under the mirror, and blood flow speed is accelerated.Intersection point is with relatively to expand capillary action before the coating remarkable.
2.6 influence to isolated rabbit ear perfusion flow
[1]
The extracting waste rabbit, the anesthesia of ear iV30mg/kg pentobarbital sodium is along the middle tremulous pulse of auricular concha, insert a syringe needle that band is protruding to blood flow direction, and fix other arterial bifurcation of ligation with surgical thread, cut the rabbit ear, use 37 ℃ of Rockwell liquid of saturated oxygen perfusion at once, fixedly the rabbit ear is on glass plate, otch is downward, perfusate is flowed down along glass plate, and perfusion pressure 60cm, flow velocity are 2ml/min, behind the stability of flow, coating around the rabbit ear is measured changes in flow rate behind coating 5,10, the 20min.Measurement result shows that test drug can obviously increase rabbit ear perfusion rate, accelerates blood circulation.High dose increases by 32%, 40%, 45% before than coating, and middle dosage increases by 53%, 53%, 53%, and low dosage increases by 19.0%, 19.0%, 9.5%.Significantly increase with comparison perfusion flow before the coating.
3 conclusions:
Result of the test shows that this medicine is coated with and can obviously improves the pain threshold that large and small Mus causes heat radiation, hot plate outward, and the inflammation that inhibition dimethylbenzene, carrageenin cause increases the open quantity of blood capillary, accelerates velocity of blood flow, microcirculation improvement.
Experimental example 2: rat long term toxicity test and documents and materials
Test is divided into matched group, high dose group, middle dosage group, low dose group with rat, and the coating area is respectively 10%, 6%, 2%, continuous 24 weeks of coating, and carry out the restorative observation of 2 all drug withdrawals.The result shows, rat sign, hemanalysis, and organ index, liver, renal function and tissue slice there is no obvious change.
Purpose is observed the long term administration rat and whether is produced toxicity, and the target organ of toxic reaction and the degree of reversibility of infringement thereof are provided, and determines toxic reaction dosage, provides reference for drafting the human safe dose.
1, material
80 of animal Wistar kind rats, body weight 58g-76g, in Mus 4-5 in age week, male and female half and half are provided by University of the Inner Mongol's Experimental Animal Center, the animal quality certification number: word 8806R011 is moved in the capital.
The medicine loud, high-pitched sound is pricked the easypro gel of network, substrate is covered the living technology of credit Co., Ltd by Inner Mongol Fudan University provides the suitable 1g medical material of every gram, lot number 20011101.
Instrument 42 type semi-automatic biochemical analyzers are made by Britain Bekman company.
The reagent biochemical reagents are produced by giving birth to engineering High-tech company in Beijing.
2, method
Experimental rat divides 4 groups, and 20 every group, every cage is raised 5, observes for 1 week before the administration, under every N/R situation of Mus, cuts off hair with operating scissors in root of the tail makes progress scope, does not hinder skin.Morning every day 8 left and right sides coatings, 2 pm is washed off with suds.Matched group is coated with same amount substrate.Observe the clinical manifestation of rat behind the coating, mainly comprise autonomic activities, hair growth, skin changes, feces character, color, dietary amount has or not the abnormal secretion thing, flatulence etc.Measure body weight weekly one time.19-23 ℃ of experimental session room temperature, relative temperature 45-70%.Continuous 24 weeks of coating (clinical course of treatment is about 30 days).Before finishing, experiment takes a blood sample by the tail point, do hemanalysis, use ether inhalation anesthesia, dissection at last, take a blood sample from ventral aorta, measure the heart, liver, kidney biochemical function, and situations such as form, color, size such as perusal heart, liver, spleen, lung, kidney, adrenal gland, thymus, testis, uterus, ovary, breast, skin, and measure relevant organ index, do the check pathological section of different tissues at last.
3, coating foundation
Get a certain amount of test drug, be coated in body weight 64-80g rat unhairing place, smear evenly, do not pile up with finger.Through the coating test, by formula calculate: Log rat body weight * 0.6981+0.8762=rat bulk area
[1]But maximum coating operations area is 10% with interior comparatively suitable.So, calculate the dynamic coating area of rat by 10%.≤ 100g rat, coating area 3 * 6cm; ≤ 200g, coating area 5 * 6cm; ≤ 300g, coating area 5 * 8cm; ≤ 400g, coating area 6 * 8cm.Being coated with dose is about every square centimeter of 0.02g.Middle dosage calculates by rat bulk area 6%, and the coating area is respectively 2 * 5cm, 3 * 3cm, 4 * 6cm, 5 * 6cm.Low dosage calculates by rat bulk area 2%, and the coating area is respectively 1 * 2cm, 2 * 3cm, 2 * 4cm, 2 * 5cm.
4, result
4.1 normal to the general clinical sign various dose coating group and the equal colour of skin of control rats, no abnormal secretions, behavior, diet are all normal, no flatulence.Show that tested medicine does not have obvious harmful effect to the general clinical sign of rat.Rat does not see untoward reaction yet behind the drug withdrawal 2W, and coating place hair growth is normal.
4.2 to continuous 24 weeks of coating of weight increase rat comparing the body weight no significant difference with matched group.Drug withdrawal 2 all back body weight and 2 all matched groups are no significant difference more also, and drug withdrawal 2 all weight increase are obvious.Show that tested medicine increases not have to rat body weight and obviously promotes and inhibitory action, also not having because of drug withdrawal makes rat body weight increases unusual or inhibitory action.
4.3 continuous coating of the tested medicine of hemanalysis various dose and matched group are compared, and hemanalysis is basically identical as a result, 2 week of drug withdrawal, the back results were also no abnormal.Show that this medicine is formed rat blood and the no obvious harmful effect of generation.
4.4 the conscience function with enzymatic assays ALT, AST, LDH, CPK, ALP, Glu, Cho, is used colorimetric method for determining ALB, measures bilirubin (T.Bil) with the diazonium method.Determination and analysis shows that this medicine does not have obvious influence to the rats'liver function.Rat does not see that the heart, liver function have ANOMALOUS VARIATIONS yet after 2 weeks of drug withdrawal.Illustrate that it is safe that this medicine is coated with usefulness for a long time.
4.5 renal function is measured BUN, Crea with end-point method, and mensuration shows that this medicine does not have obvious harmful effect to the kidney of rats function, the also no abnormality seen variation of 2 week of drug withdrawal back kidney of rats function.
4.6 to the rat anatomic observation
Administration 24 week back and respectively organize rat after 2 weeks of drug withdrawal and all use ether inhalation anesthesia, and dissect at once, make its death from the abdominal aortic cannulation blood-letting.By digestion, urinary system, reproduction, endocrine, breathing, circulation, cental system carries out perusal; The digestive system emphasis is watched liver, spleen, SDP gland; Urinary system is watched kidney; Reproductive system is watched testis, epididymis, prostate, seminal vesicle, uterus, ovary; Hormonal system is watched adrenal gland, thyroid, thymus; Respiratory circulatory system is watched lung, the heart; Cental system is watched brain, cerebellum, brain stem.Mainly watch size, color, form, adhesion, blood stasis, ulcer, hydrops, swollen unusually thing, flatulence.
No hydrops in each rats in test groups pericardium of heart, heart surface is dark red smooth, no blood stasis, ventricle and atrium boundary are obvious, and coronary artery does not have blood stasis, and the visible left and right ventricles structure of heart tangent plane is normal.
Each rats in test groups liver of liver is mulberry, lustrous surface, and the edge is sharp, and each lobe of the liver and perienchyma do not have adhesion, and necrosis region, parasitic cyst and hepatomegaly are not seen in the surface.Common bile duct bile is full, and is clog-free.
Spleen is respectively organized the rat spleen and is taken on a red color, big or small basically identical.The surface is slightly coarse, and the edge circle is blunt, cuts the face uniform and smooth.
Stomach, duodenum and pancreas stomach outward appearance do not have ulcer, and the division is clearly demarcated for glandular stomach, cud, and gastric food is faintly visible, cuts off along greater gastric curvature, and water washes away the gastric thing, the glandular stomach mucosa cauliflower form that is white in color, mucosa not damaged; The duodenum soft smooth does not have ulcer, and pylorus junction incisura is obvious.Visible common bile duct there is no abnormal conditions in duodenum place connective tissue; As seen the duodenum right side slightly is pink colour, liparoid pancreatic tissue, solid colour, no adhesion in the connective tissue of stomach bottom.
Testis, epididymis testis retraction intraperitoneal or in the testis sheath, no hydrops in the sheath, the traveling of epiorchium blood vessel is obvious, no blood stasis in the blood vessel, interior visible white mucus of testis and spermatogenesis pipe; Epididymis is attached in the testis external fat, and big or small basically identical is faint yellow, and matter is harder.All rat testicle, epididymis are grown normal.
Prostate, seminal fluid capsule are spongy the visible prostate leaflet of bladder root; Seminal fluid is met the air after coagulation in the seminal fluid capsule.Apparent size, color and luster basically identical there is no ANOMALOUS VARIATIONS.
Uterus, ovary are respectively organized the ♀ rat uterus and are triangular shape, and thickness does not wait, and some perimetrium blood vessel traveling is obvious, cut the visible phlegmatic temperament in uterus, and mucosa is satiny; What upper corners visible fat in uterus wrapped up is the ovary of purple grape shape, differs in size.Uterus, ovary there is no unusually.
The adrenal gland is round triangle, is wrapped in the other connective tissue of kidney, takes on a red color, and size is consistent, no atrophy.
Each rats in test groups thyroid size basically identical of thyroid is flesh pink, is grown in the thyroid cartilage both sides, no abnormality seen.
Thymus is fat white above the thoracic cavity, the edge is sharp, and is plentiful, and leaflet is arranged, no atrophy.
Brain, cerebellum, brain stem are cut off skull with shears along vertebral foramen, and the cerebral cortex ditch returns high-visible, and the blood vessel traveling is obvious, and the meninges vascular surface is not seen blood stasis, also do not see other focus; The hemisphaerium cerebelli ditch returns and is screw-like; The bottom brain stem is symmetric projection, big or small basically identical.
4,7 organ coefficients are measured and the heart, liver, spleen, lung, kidney, brain, adrenal gland, thymus, thyroid, ovary, uterus, testis, epididymis assessment of indices are shown this medicine does not have hypertrophy or the atrophy that causes because of infringement to rat different organs and gland tissue.
4,24 all coating rats and the control rats heart, liver, spleen, lung, kidney, adrenal gland, thymus, thyroid, uterus, ovary, testis, epididymis, prostate, pancreas, brain, stomach, duodenum are got in 8 tissue slice inspections, coating skin is done check pathological section, to 2 weeks after the drug withdrawal respectively organizing rat and corresponding control rats different tissues is done same pathological section.The result does not all find obvious pathological change, with the matched group basically identical.
4, conclusion
Loud, high-pitched sound is pricked the easypro gel of network and is coated in the unhairing place with rat body surface area 10%, 6%, 2%, about every square centimeter of about 0.02g, washes ointment off with suds behind the coating 6h, continuously 24 weeks of coating.The result shows, this medicine is to rat body weight, dietary amount, and spontaneous activity, peripheral hemogram, the heart, liver, kidney biochemical function, internal organs are dissected and are checked that linked groups's pathology cut sections for microscopic examination are not all found because of drug-induced toxic reaction.Drug withdrawal 2 convalescent period in week rat observation and above-mentioned index of correlation mensuration are not seen because of drug-induced tardy property toxic reaction yet.Hair growth is normal after the skin drug withdrawal of coating place, and the hair that drug withdrawal 2 all coatings place skins are newly grown substantially covers.It is safe in utilization that the easypro gel external of network is pricked in evidence, loud, high-pitched sound.
Embodiment 1:
The preparation of medicament gelling agent of the present invention
(a): take by weighing each crude drug Radix Aconiti Kusnezoffii 120g, Rhizoma Chuanxiong 240g and Radix Notoginseng 25g, standby;
(b): the 120g Radix Aconiti Kusnezoffii is ground into coarse powder with 6 times of amount 50% ethanol percolations, collects percolate;
(c): with Rhizoma Chuanxiong 240g and Radix Notoginseng 25g, be ground into coarse powder, collect percolate with 6 times of amount 50% ethanol percolations;
(d): merge (b), (c) percolate reclaims ethanol to the thick paste shape, adds triethanolamine 5g, propylene glycol 50g, and tween 80 10g stirs;
(e): it is 1%～3% that the mixture of (d) is added to concentration, in the 20g carbomer liquid, fully stirs, and grinds and promptly gets the gel finished product.
Embodiment 2: the preparation of medicinal tincture of the present invention
Get Radix Aconiti Kusnezoffii 360g, Rhizoma Chuanxiong 480g and Radix Notoginseng 100g are ground into coarse powder with 5 times of amount 90% ethanol percolations, collect percolate; Promptly.
Embodiment 3: the preparation of medicine liniment of the present invention
(a): take by weighing each crude drug Radix Aconiti Kusnezoffii 200g, Rhizoma Chuanxiong 300g and Radix Notoginseng 50g, standby;
(b): the 360g Radix Aconiti Kusnezoffii is ground into coarse powder with 8 times of amount 70% ethanol percolations, collects percolate;
(c): with Rhizoma Chuanxiong 300g and Radix Notoginseng 50g, be ground into coarse powder, collect percolate with 9 times of amount 70% ethanol percolations;
(d): merge (b), (c) percolate, concentrating under reduced pressure adds dibutyl phthalate 11 grams and polyvinyl alcohol acetone 20 grams, after waiting to dissolve, adds polyvinyl formal-acetal 30 grams again, and the limit edged stirs, to all dissolvings, promptly.
Embodiment 4: the preparation of medicament gelling agent of the present invention
(a): take by weighing each crude drug Radix Aconiti Kusnezoffii 300g, Rhizoma Chuanxiong 450g and Radix Notoginseng 80g, standby;
(b): the 300g Radix Aconiti Kusnezoffii is ground into coarse powder with 8.5 times of amount 70% ethanol percolations, collects percolate;
(c): with Rhizoma Chuanxiong 450g and Radix Notoginseng 80g, be ground into coarse powder, collect percolate with 9 times of amount 75% ethanol percolations;
(d): merge (b), (c) percolate reclaims ethanol to the thick paste shape, adds triethanolamine 15g, propylene glycol 120g, and tween 80 45g stirs;
(e): it is 1%～3% that the mixture of (d) is added to concentration, in the 30g carbomer liquid, fully stirs, and grinds and promptly gets the gel finished product.
Embodiment 5: the preparation of medicament gelling agent of the present invention
(a): take by weighing each crude drug Radix Aconiti Kusnezoffii 260g, Rhizoma Chuanxiong 430g and Radix Notoginseng 50g, standby;
(b): the 260g Radix Aconiti Kusnezoffii is ground into coarse powder with 8 times of amount 85% ethanol percolations, collects percolate;
(c): with Rhizoma Chuanxiong 430g and Radix Notoginseng 5g, be ground into coarse powder, collect percolate with 10 times of amount 65% ethanol percolations;
(d): merge (b), (c) percolate reclaims ethanol to the thick paste shape, adds triethanolamine 15g, propylene glycol 85g, and tween 80 40g stirs;
(e): it is 1%～3% that the mixture of (d) is added to concentration, in the 25g carbomer liquid, fully stirs, and grinds and promptly gets the gel finished product.
Embodiment 6: the preparation of medicament gelling agent of the present invention
(a): take by weighing each crude drug Radix Aconiti Kusnezoffii 120g, Rhizoma Chuanxiong 240g, Radix Notoginseng 25g and Rhizoma Kaempferiae 200g, standby;
(b): the 120g Radix Aconiti Kusnezoffii is ground into coarse powder with 6 times of amount 70% ethanol percolations, collects percolate;
(c): with Rhizoma Chuanxiong 240g, Radix Notoginseng 25g and Rhizoma Kaempferiae 200g are ground into coarse powder with 6 times of amount 60% ethanol percolations, collect percolate;
(d): merge (b), (c) percolate reclaims ethanol to the thick paste shape, adds triethanolamine 10g, propylene glycol 85g, and tween 80 30g stirs;
(e): it is 1%～3% that the mixture of (d) is added to concentration, in the 20g carbomer liquid, fully stirs, and grinds and promptly gets the gel finished product.
Embodiment 7: the preparation of medicine rubber-emplastrum of the present invention
(a): take by weighing each crude drug Radix Aconiti Kusnezoffii 360g, Rhizoma Chuanxiong 480g, Radix Notoginseng 100g and Rhizoma Kaempferiae 480g, standby;
(b): the 360g Radix Aconiti Kusnezoffii is ground into coarse powder with 10 times of amount 90% ethanol percolations, collects percolate;
(c): with Rhizoma Chuanxiong 480g, Radix Notoginseng 100g and Rhizoma Kaempferiae 480g are ground into coarse powder with 12 times of amount 90% ethanol percolations, collect percolate;
(d): merge (b), (c) percolate is made relative density and is 1.00～1.20 fluid extract;
(e), with above-mentioned fluid extract, add 3.5～4.0 times of weight substrate, make coating and be coated with cream, cut off, the lid lining is cut into small pieces, promptly.
Embodiment 8: the preparation of medicament gelling agent of the present invention
(a): take by weighing each crude drug Radix Aconiti Kusnezoffii 200g, Rhizoma Chuanxiong 300g, Radix Notoginseng 50g and Rhizoma Kaempferiae 240g, standby;
(b): the 200g Radix Aconiti Kusnezoffii is ground into coarse powder with 7 times of amount 60% ethanol percolations, collects percolate;
(c): with Rhizoma Chuanxiong 300g, Radix Notoginseng 50g and Rhizoma Kaempferiae 240g are ground into coarse powder with 7 times of amount 65% ethanol percolations, collect percolate;
(d): merge (b), (c) percolate reclaims ethanol to the thick paste shape, adds triethanolamine 10g, propylene glycol 85g, and tween 80 30g stirs;
(e): it is 1%～3% that the mixture of (d) is added to concentration, in the 25g carbomer liquid, fully stirs, and grinds and promptly gets the gel finished product.
Embodiment 9: the medicine for external use of Drug therapy peripheral neuritis of the present invention, by following each this Chinese medicine of weight proportion, each crude drug Radix Aconiti Kusnezoffii 300g wherein, Rhizoma Chuanxiong 450g, Radix Notoginseng 80g and Rhizoma Kaempferiae 400g, required various adjuvants in the time of can adding the different exterior-applied formulation of preparation are prepared into any exterior-applied formulation commonly used.
Embodiment 10: the medicine for external use of Drug therapy peripheral neuritis of the present invention, by following each this Chinese medicine of weight proportion, each crude drug Radix Aconiti Kusnezoffii 260g wherein, Rhizoma Chuanxiong 420g, Radix Notoginseng 70g and Rhizoma Kaempferiae 260g, required various adjuvants in the time of can adding the different exterior-applied formulation of preparation are prepared into any exterior-applied formulation commonly used.
Embodiment 11: the medicine for external use of Drug therapy peripheral neuritis of the present invention, and by following each this Chinese medicine of weight proportion, each crude drug Radix Aconiti Kusnezoffii 120g wherein, Rhizoma Chuanxiong 240g, Radix Notoginseng 25g, Rhizoma Kaempferiae 200g, Rhizoma Corydalis 50g and Rhizoma Curcumae Longae 80g.Required various adjuvants in the time of can adding the different exterior-applied formulation of preparation are prepared into any exterior-applied formulation commonly used.
Embodiment 12: the medicine for external use of Drug therapy peripheral neuritis of the present invention, and by following each this Chinese medicine of weight proportion, each crude drug Radix Aconiti Kusnezoffii 360g wherein, Rhizoma Chuanxiong 480g, Radix Notoginseng 100g, Rhizoma Kaempferiae 480g, Rhizoma Corydalis 160g and Rhizoma Curcumae Longae 160g.Required various adjuvants in the time of can adding the different exterior-applied formulation of preparation are prepared into any exterior-applied formulation commonly used.
Embodiment 13: the medicine for external use of Drug therapy peripheral neuritis of the present invention, and by following each this Chinese medicine of weight proportion, each crude drug Radix Aconiti Kusnezoffii 200g wherein, Rhizoma Chuanxiong 300g, Radix Notoginseng 50g, Rhizoma Kaempferiae 240g, Rhizoma Corydalis 80g and Rhizoma Curcumae Longae 100g.Required various adjuvants in the time of can adding the different exterior-applied formulation of preparation are prepared into any exterior-applied formulation commonly used.
Embodiment 14: the medicine for external use of Drug therapy peripheral neuritis of the present invention, and by following each this Chinese medicine of weight proportion, each crude drug Radix Aconiti Kusnezoffii 300g wherein, Rhizoma Chuanxiong 450g, Radix Notoginseng 80g, Rhizoma Kaempferiae 400g, Rhizoma Corydalis 130g and Rhizoma Curcumae Longae 120g.Required various adjuvants in the time of can adding the different exterior-applied formulation of preparation are prepared into any exterior-applied formulation commonly used.
Embodiment 15: the medicine for external use of Drug therapy peripheral neuritis of the present invention, and by following each this Chinese medicine of weight proportion, each crude drug Radix Aconiti Kusnezoffii 250g wherein, Rhizoma Chuanxiong 420g, Radix Notoginseng 60g, Rhizoma Kaempferiae 260g, Rhizoma Corydalis 90g and Rhizoma Curcumae Longae 100g.Required various adjuvants in the time of can adding the different exterior-applied formulation of preparation are prepared into any exterior-applied formulation commonly used.
Claims (12)
1, the medicine for external use of treatment peripheral neuritis is characterized in that it mainly is to be made by following bulk drugs, 120～360 parts of Radix Aconiti Kusnezoffii, 25～100 parts of 240～480 parts of Rhizoma Chuanxiongs and Radix Notoginseng.
2, a kind of medicine for external use for the treatment of peripheral neuritis according to claim 1 is characterized in that, 200～300 parts of described raw material Radix Aconiti Kusnezoffii, 300～450 parts of Rhizoma Chuanxiongs, 50～80 parts of Radix Notoginseng.
3, a kind of medicine for external use for the treatment of peripheral neuritis according to claim 2 is characterized in that wherein the consumption of each crude drug is: 260 parts of Radix Aconiti Kusnezoffii, 430 parts of Rhizoma Chuanxiongs, 50 parts of Radix Notoginseng.
4, according to claim 1,2 or 3 described a kind of production methods for the treatment of the medicine for external use of peripheral neuritis, it is characterized in that it includes the following step:
(a): take by weighing each crude drug Radix Aconiti Kusnezoffii, Rhizoma Chuanxiong, Radix Notoginseng, standby;
(b): the Radix Aconiti Kusnezoffii of described weight proportion is ground into coarse powder with 6～10 times of amount 50%～90% ethanol percolations, collects percolate;
(c): with Rhizoma Chuanxiong, the Radix Notoginseng of described weight proportion, be ground into coarse powder, collect percolate with 6～12 times of amount 50%～95% ethanol percolations;
(d): merge (b), (c) percolate reclaims ethanol to the thick paste shape, 5～20 parts of the triethanolamine of adding weight portion proportioning, and 50～150 parts of propylene glycol, 10～60 parts of tween 80s stir;
(e): it is in 1%～3% carbomer liquid that the mixture of (d) is added to concentration, and its weight portion proportioning is 20～50 parts, fully stirs, and grinds and promptly gets the gel finished product.
5, according to right 1 described a kind of medicine for external use for the treatment of peripheral neuritis, it is characterized in that its crude drug also includes 200～480 parts of Rhizoma Kaempferiaes.
6, according to right 5 described a kind of medicine for external use for the treatment of peripheral neuritis, it is characterized in that 200～300 parts of described raw material Radix Aconiti Kusnezoffii, 300～450 parts of Rhizoma Chuanxiongs, 50～80 parts of Radix Notoginseng, 240～400 parts of Rhizoma Kaempferiaes.
7, according to right 6 described a kind of medicine for external use for the treatment of peripheral neuritis, it is characterized in that 260 parts of described raw material Radix Aconiti Kusnezoffii, 420 parts of Rhizoma Chuanxiongs, 70 parts of Radix Notoginseng, 260 parts of Rhizoma Kaempferiaes.
8, according to claim 5 or 6 described a kind of production methods for the treatment of the medicine for external use of peripheral neuritis, it is characterized in that it includes the following step:
(a): take by weighing each crude drug Radix Aconiti Kusnezoffii, Rhizoma Chuanxiong, Radix Notoginseng, Rhizoma Kaempferiae is standby;
(b): the Radix Aconiti Kusnezoffii of described weight proportion is ground into coarse powder with 6～10 times of amount 50%～90% ethanol percolations, collects percolate;
(c): with Rhizoma Chuanxiong, the Radix Notoginseng of described weight proportion, Rhizoma Kaempferiae is ground into coarse powder with 6～12 times of amount 50%～95% ethanol percolations, collects percolate;
(d): merge (b), (c) percolate reclaims ethanol to the thick paste shape, 5～20 parts of the triethanolamine of adding weight portion proportioning, and 50～150 parts of propylene glycol, 10～60 parts of tween 80s stir;
(e): it is in 1%～3% carbomer liquid that the mixture of (d) is added to concentration, and its weight portion proportioning is 20～50 parts, fully stirs, and grinds and promptly gets the gel finished product.
9, according to right 5 described a kind of medicine for external use for the treatment of peripheral neuritis, it is characterized in that its crude drug also includes 50～160 parts of Rhizoma Corydalis, 80～160 parts in Rhizoma Curcumae Longae.
10, according to right 9 described a kind of medicine for external use for the treatment of peripheral neuritis, it is characterized in that 200～300 parts of Radix Aconiti Kusnezoffii, 300～450 parts of Rhizoma Chuanxiongs, 50～80 parts of Radix Notoginseng, 240～400 parts of Rhizoma Kaempferiaes, 80～130 parts of Rhizoma Corydalis, 80～120 parts in Rhizoma Curcumae Longae.
11, according to right 10 described a kind of medicine for external use for the treatment of peripheral neuritis, it is characterized in that 250 parts of Radix Aconiti Kusnezoffii, 420 parts of Rhizoma Chuanxiongs, 60 parts of Radix Notoginseng, 260 parts of Rhizoma Kaempferiaes, 90 parts of Rhizoma Corydalis, 100 parts in Rhizoma Curcumae Longae.
12, according to claim 9,10 or 11 described a kind of production methods for the treatment of the medicine for external use of peripheral neuritis, it is characterized in that it includes the following step:
(a): take by weighing each crude drug Radix Aconiti Kusnezoffii, Rhizoma Chuanxiong, Radix Notoginseng, Rhizoma Kaempferiae, Rhizoma Corydalis, Rhizoma Curcumae Longae is standby;
(b): the Radix Aconiti Kusnezoffii of described weight proportion is ground into coarse powder with 6～10 times of amount 50%90% ethanol percolations, collects percolate;
(c): with Rhizoma Chuanxiong, Radix Notoginseng, the Rhizoma Kaempferiae of described weight proportion, Rhizoma Corydalis, Rhizoma Curcumae Longae is ground into coarse powder with 6～12 times of amount 50%～95% ethanol percolations, collects percolate;
(d): merge (b), (c) percolate reclaims ethanol to the thick paste shape, 5～20 parts of the triethanolamine of adding weight portion proportioning, and 50～150 parts of propylene glycol, 10～60 parts of tween 80s stir;
(e): it is in 1%～3% carbomer liquid that the mixture of (d) is added to concentration, and its weight portion proportioning is 20～50 parts, fully stirs, and grinds promptly get loud, high-pitched sound and prick the easypro gel finished product of network.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510009240 CN1281238C (en) | 2005-02-01 | 2005-02-01 | External-applied medicine for treating terminal neuritis and preparation thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510009240 CN1281238C (en) | 2005-02-01 | 2005-02-01 | External-applied medicine for treating terminal neuritis and preparation thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1679717A true CN1679717A (en) | 2005-10-12 |
| CN1281238C CN1281238C (en) | 2006-10-25 |
Family
ID=35066723
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200510009240 Active CN1281238C (en) | 2005-02-01 | 2005-02-01 | External-applied medicine for treating terminal neuritis and preparation thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1281238C (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103251916A (en) * | 2013-05-21 | 2013-08-21 | 徐笑群 | Chinese herb preparation for treating peripheral neuritis |
| CN105250569A (en) * | 2015-11-26 | 2016-01-20 | 王茂凯 | Traditional Chinese medicine pill for treating peripheral neuritis and preparation method |
-
2005
- 2005-02-01 CN CN 200510009240 patent/CN1281238C/en active Active
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103251916A (en) * | 2013-05-21 | 2013-08-21 | 徐笑群 | Chinese herb preparation for treating peripheral neuritis |
| CN103251916B (en) * | 2013-05-21 | 2014-11-05 | 徐笑群 | Chinese herb preparation for treating peripheral neuritis |
| CN105250569A (en) * | 2015-11-26 | 2016-01-20 | 王茂凯 | Traditional Chinese medicine pill for treating peripheral neuritis and preparation method |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1281238C (en) | 2006-10-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1239187C (en) | Chinese medicine composition for curing chronic atrophic sastritis and its preparing method and quality control method | |
| CN1947739A (en) | Traditional Chinese medicine composition for treating dermal titillation and chronic eczema and its prepn. method | |
| CN1813868A (en) | Composition for treating and improving chronic fatigue syndrome and its preparing method | |
| CN101062377A (en) | Adhesive plaster for diminishing inflammation, expelling wind and cold and so on and its preparation method | |
| CN1281238C (en) | External-applied medicine for treating terminal neuritis and preparation thereof | |
| CN1772136A (en) | Medicine composition for treating soft tissue damage and osteoarthropathy and its prepn process | |
| CN1660356A (en) | Combination of Tibet medicine of containing salt and possessing medicinal effect health care, and preparation metohd | |
| CN101028325A (en) | Medicinal composition containing sailonggu, and its preparation and quality control | |
| CN1194735C (en) | Chinese medicine for treating hyperplasia of mammary glands | |
| CN1559495A (en) | Deer's fetus granular Chinese madicinal preparation and its production technology | |
| CN1836685A (en) | Use of catechu in preparing drug for treating hyperuricemia | |
| CN101062085A (en) | Condyloma acuminata treating medicine | |
| CN1136880C (en) | Combined Chinese and Western medicine for treating bronchial asthma | |
| CN1820770A (en) | Chinese medicine composition for treating apoplexy and its preparing method | |
| CN1313085C (en) | Application of total hypone of radix cynanchi bungei and hypnone for preparing medicine for treating gastrointestinal tract diseases | |
| CN1582952A (en) | Use of asiaticoside in preparation of medicines for diseases of cardio-cerebral blood vessels | |
| CN1751738A (en) | Traditional Chinese medicine Babuji for treating arthritis, omitis and hyperosteogeny and its prepn. method | |
| CN1197611C (en) | Medicine for curing choleithiasis and preparing method thereof | |
| CN111643606B (en) | Gel plaster for treating insomnia and preparation method thereof | |
| CN1660865A (en) | Saponin compound, general saponin of cynanchum bunaei and application in medication for treating disease of gstrointestinal tract | |
| CN1179735C (en) | Litholytic medicine for treating hepatolith and preparation process thereof | |
| CN1065764C (en) | Quickly-acting antalgesic liniment and its preparing process | |
| CN1634299A (en) | Application of fenugreek total alkali extract in preparing medicine for ulcerative colitis and preparation method of colon targeted preparation | |
| CN1541691A (en) | Acute icterohepatitis treating Chinese traditional medicine and its preparation | |
| CN1478469A (en) | Capsule possessing antiinflammation, releaving pain and anticancer function and its preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C57 | Notification of unclear or unknown address | ||
| DD01 | Delivery of document by public notice |
Addressee: Bai Shilei Document name: Notification to Pay the Fees |
|
| DD01 | Delivery of document by public notice |
Addressee: Bai Shilei Document name: Notification to Pay the Fees |
|
| DD01 | Delivery of document by public notice |
Addressee: Bai Shilei Document name: Notification of Termination of Patent Right |
|
| ASS | Succession or assignment of patent right |
Owner name: INNER MONGOLIA YUANHE PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: FUDAN MENGYAO BIOTECH CO., LTD., INNER MONGOLIA Effective date: 20130925 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20130925 Address after: Jinchuan District 010080 the Inner Mongolia Autonomous Region Hohhot economic and Technological Development Zone gold two Patentee after: Inner Mongolia Yuanhe Pharmaceutical Co., Ltd. Address before: 010080, the Inner Mongolia Autonomous Region Hohhot Jinchuan Development Zone Management Committee on the eastern side of Fudan Yao Yao Biological Park Patentee before: Neimenggu Fu Dan Meng Yao Bio-technology Co., Ltd. |
|
| C56 | Change in the name or address of the patentee | ||
| CP03 | Change of name, title or address |
Address after: The 010080 the Inner Mongolia Autonomous Region economic and Technological Development Zone of Hohhot district two gold Patentee after: YUANHE PHARMACEUTICAL CO., LTD. Address before: Jinchuan District 010080 the Inner Mongolia Autonomous Region Hohhot economic and Technological Development Zone gold two Patentee before: Inner Mongolia Yuanhe Pharmaceutical Co., Ltd. |